Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Stilonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 19/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 10/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 10/20 | 1.00 |
| ▸ | CHRNA10 | Q9GZZ6 | 5/20 | 1.00 |
| ▸ | CHRNA9 | Q9UGM1 | 5/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 4/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 4/20 | 1.00 |
| ▸ | APOBEC3A | P31941 | 1/20 | 1.00 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 1.00 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stilonium SCHEMBL26105 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB4CHRNA3CHRNA10CHRNA9 | |
| Stilonium SCHEMBL10197132 | 0.98 | CHRNA7 (1.00) | CHRNA7CHRNB4CHRNA3CHRNA10CHRNA9 | |
| SCHEMBL13385235 | 0.83 | CHRNA7 (1.00) | CHRNA7CHRNB4CHRNA3CHRNA10CHRNA9 | |
| Hydrochloric Acid SCHEMBL11423649 | 0.81 | CHRNA7 (0.96) | CHRNA7CHRNB4CHRNA3CHRNA10CHRNA9 | |
| SCHEMBL1618632 | 0.80 | RELA (0.72) | CHRNA7CHRNB4CHRNA3CHRNA10CHRNA9 | |
| SCHEMBL5741015 | 0.80 | RELA (0.72) | CHRNA7CHRNB4CHRNA3CHRNA10CHRNA9 | |
| SCHEMBL80814 | 0.76 | CHRNA7 (0.72) | CHRNA7CHRNB4CHRNA3CHRNA10CHRNA9 | |
| SCHEMBL436231 | 0.76 | RELA (1.00) | CHRNA7CHRNB4CHRNA3CHRNA10CHRNA9 | |
| SCHEMBL5496245 | 0.76 | RELA (1.00) | CHRNA7CHRNB4CHRNA3CHRNA10CHRNA9 | |
| SCHEMBL5739190 | 0.76 | CHRNA7 (0.68) | CHRNA7CHRNB4CHRNA3CHRNA10CHRNA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 764 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112237631-B | Use of acetylcholine pathway modulators in the treatment of cancer | 清华大学 | 2022-03-04 | — | — | CN | claimed |
| US-10383510-B2 | Implant with high vapor pressure medium | SOLACE THERAPEUTICS, INC. (US) | 2019-08-20 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-2367503-A1 | IMPLANT WITH HIGH VAPOR PRESSURE MEDIUM | AttenueX Technologies, Inc. (US) | 2011-09-28 | — | — | EP | claimed |
| US-20100222802-A1 | IMPLANT WITH HIGH VAPOR PRESSURE MEDIUM | ATTENUEX TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | US | claimed |
| WO-2010068467-A1 | IMPLANT WITH HIGH VAPOR PRESSURE MEDIUM | ATTENUEX TECHNOLOGIES, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| EP-1879578-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2009-05-13 | — | — | EP | claimed |
| EP-1879578-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV Pharmaceutical Inc. (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2006102029-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2006-12-07 | — | — | WO | claimed |
| WO-2006102029-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-4168092-B1 | BALLOON CATHETER WITH PRECISION DRUG-ELUTING CAPABILITY | BARD INC C R (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-0737066-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |